Details of the Drug Combinations

General Information of This Drug (ID: DMDI43Y)

Drug Name

BGB-324 DMDI43Y

Synonyms

BGB-001; SiRNA therapeutic (metastasis cancer), BiobergenBio

Indication

Disease Entry	ICD 11	Status	REF
Breast cancer	2C60-2C65	Phase 2	[1]
Acute myeloid leukaemia	2A60	Phase 1/2	[2]
Myelodysplastic syndrome	2A37	Phase 1/2	[1]
Metastatic malignant neoplasm	2D50-2E09	Investigative	[3]
------------------------------------------------------------------------------------

Drug Type

siRNA drug

List of Combinatorial Drugs (CBD) Containing This Drug

1 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
BGB-324 + Panobinostat	DCIB9WL	Panobinostat	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[4]
------------------------------------------------------------------------------------

2 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
BGB-324 + Decitabine	DC13J29	Decitabine	Acute Myeloid Leukemia	[5]
Erlotinib + BGB-324	DCNCRCV	Erlotinib	Non-Small Cell Lung Cancer	[6]
------------------------------------------------------------------------------------

References

1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1835).
4	Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
5	ClinicalTrials.gov (NCT02488408) A Phase Ib/II Multicenter Open-label Study of Bemcentinib (BGB324) in Patients With AML or MDS
6	ClinicalTrials.gov (NCT02424617) A Study of BGB324(Bemcentinib) in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer